INTESTINAL PARASITE GUIDELINES FOR DOMESTIC MEDICAL EXAMINATION FOR NEWLY ARRIVED REFUGEES

U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
National Center for Emerging and Zoonotic Infectious Diseases

Division of Global Migration and Quarantine

November 6, 2013
Domestic Intestinal Parasite Guidelines

Presumptive Treatment and Screening for Strongyloidiasis, Schistosomiasis and Infections Caused by Soil-Transmitted Helminths for Refugees

Introduction

It is estimated that more than one billion people are infected with soil-transmitted helminths (STH), 200 million with *Schistosoma* spp., and 100 million with *Strongyloides*. These parasites are some of the most common infections in refugees. Although frequently asymptomatic or sub-clinical, these infections may cause significant illness and even result in death. Parasites that infect humans represent a very complex and broad category of organisms. This section of the guidelines will address the parasitic infections most commonly encountered in refugees but will focus on soil-transmitted helminthic infections (*Ascaris, Trichuris, hookworm*), *Strongyloides*, and *Schistosoma* spp.

Epidemiology

Most refugees are at risk for parasitic infection. Prevalence data for parasitic infections in refugees in the United States are largely derived from stool and serologic surveys. These surveys have revealed high rates of certain infections in most refugee populations such as soil-transmitted helminth infections, *Strongyloides* and intestinal protozoal infections. In addition, they also show that there are some parasitic infections that are more frequently observed in certain populations such as *Schistosoma* spp. infections in sub-Saharan African (SSA) refugees. The overall prevalence of potentially pathogenic parasites among refugees resettled in North America has been reported to range from 8% to 86%. This broad range can be explained by differences in geographic origin, age, living conditions (including quality of drinking water, sanitation, and access to footwear), dietary habits, occupational history, education level, and previous countries of exposure/asylum in the populations studies. In addition, the variation in prevalence may be due to the type of sample tested (e.g., stool or serum) and methodologic differences among tests performed in different studies.

Since the initiation of presumptive predeparture albendazole (1999), prevalence of soil-transmitted helminths detected among refugees following arrival in the United States have dramatically decreased. However, the regimen of a single dose of albendazole has little or no effect against other important parasitic infections. Of particular concern are two parasitic infections commonly encountered in refugee populations: *Strongyloides stercoralis* (nematode) and *Schistosoma* spp. (trematode). *Strongyloides* infection is found in many refugee populations but is particularly prevalent among Southeast Asian refugees. *Schistosoma* spp. infections are encountered predominantly in SSA refugees. The prevalence of these parasitic infections was initially under-recognized since most early studies utilized only routine stool testing, a poor technique for detection of these particular organisms. Both strongyloidiasis and schistosomiasis are considered chronic infections and both have been associated with morbidity and mortality years after migration.

As many as 100 million persons worldwide are estimated to be chronically infected with *Strongyloides*. Prevalence in serosurveys of refugee populations range from 11–69% infected. Unlike most parasitic infections which are unable to replicate in the human host, *Strongyloides* is able to replicate and auto-infect causing infection that may persist for decades. If the condition is not detected promptly after arrival, data indicate that the average time to diagnosis in the United States is more than 5 years after migration. In fact, one study found that 24% of Laotian refugees had continued strongyloidiasis an average of 12 years after migration. *Strongyloides* hyperinfection syndrome may occur many years after migration to a non-endemic setting, with case reports occurring >50 years after last known exposure. Hyperinfection syndrome, triggered when large numbers of parasites infiltrate internal organs, results in fatality rates exceeding 50%. The syndrome is generally induced when an individual is placed on corticosteroids although other immunosuppressive conditions such as cancer and transplant chemotherapeutic immunosuppression may also trigger hyperinfection syndrome.

More than 200 million people worldwide are estimated to be infected with schistosomiasis. The seroprevalence in SSA refugees ranges from 15-46%. Infection with schistosomiasis may persist in humans for more than 25 years and has been associated with many sequelae depending on the species, the parasite load and the host response. Schistosomiasis is associated with liver cirrhosis and resulting clinical complications (*S. mansoni, S. japonicum*), squamous cell carcinoma of the bladder (*S. haematobium*), and urinary tract obstruction and renal failure (*S. haematobium*). Potentially devastating clinical manifestations...
Occasionally occur when the parasite egg enters the systemic circulation and travels to a normally sterile site within the body, causing severe inflammation. Eggs may travel to any part of the body, including the brain and spinal cord where the inflammatory response to the egg may cause paralysis or myelitis.

### History and evolution of the predeparture presumptive treatment for parasites in US-bound refugees

In 1997, a CDC pilot project evaluated single dose albendazole presumptive treatment in U.S.-bound Barawan Somali refugees. This project demonstrated decreases in soil-transmitted parasites with presumptive treatment. In May 1999, CDC extended this recommendation to all refugees resettling from Africa and Asia. In 2008 the recommendation was extended to refugees from the Middle East. Currently, most refugees from these countries without a contraindication are receiving a single dose of albendazole prior to departure. A table of countries that are currently implementing these pre-departure presumptive treatments can be found [here](#).

Data increasingly suggest that predeparture albendazole treatment has dramatically decreased the overall prevalence of soil-transmitted helminth infections in refugees. A recent evaluation of more than 26,000 African and Asian refugees demonstrated single dose albendazole resulted in an absolute reduction of the prevalence of any soil-transmitted helminth from 20.8% to 4.7% as measured by stool ova and parasite (O&P) examination. Albendazole-treated refugees were less likely than untreated refugees to have any nematode (prevalence ratio (PR), 0.19), *Ascaris* (PR 0.06), hookworm (PR 0.07), or *Trichuris* (PR, 0.27). These findings support previous data in African refugees resettling to the United States showing similar decrease in soil-transmitted helminths following implementation of predeparture albendazole treatment. However, despite this documented decrease in the overall prevalence of soil-transmitted helminth infections, a single dose of albendazole has very limited effect on infection with *Strongyloides* and no effect against *Schistosoma* spp.

Due to documented high rates of infection in refugee populations and increasing reports of serious clinical consequences, in 2005 CDC issued recommendations for predeparture treatment for strongyloidiasis (in all Middle Eastern, Asian, and African refugees) as well as for schistosomiasis (in SSA refugees only). These guidelines treat refugees from non-*Loa loa* endemic countries. In addition, as of January 2010, presumptive predeparture treatment for schistosomiasis with praziquantel is recommended for SSA refugees who do not have contraindications (Table 1). However, institution of these recommendations was variable due to funding restrictions and logistical challenges. A table of countries that are currently implementing these pre-departure presumptive treatments can be found [here](#).

### Predeparture presumptive treatment

Certain populations may not receive predeparture presumptive treatment. In addition, specific individuals within each population may not be eligible for certain predeparture medications due to pregnancy, breastfeeding, young age, or other contraindications, such as known hypersensitivity or allergies and history of seizures or known neurocysticercosis. Thus, post-arrival guidelines are designed to be flexible and are contingent upon whether the predeparture presumptive treatment was received. Ideally, the clinician will have documentation of presumptive therapy received by each individual at the time of new arrival screening. However, it is recognized that currently this documentation is not consistently available. *In cases when the documentation is not available it is reasonable to assume presumptive treatment has been received by the individual refugee if the refugee is from a population where the program is currently implemented and as long as they had no contraindications at the time of departure.* CDC periodically monitors ongoing programs and has documented 75-100% compliance rates in populations that are currently treated. If a country does not appear on this table, then compliance rates in that country are uncertain, so the clinician should use their judgment regarding screening the refugee or providing presumptive treatment.

An algorithm has been developed based on current programming to assist the post-arrival clinician in the management of parasites in newly arriving refugees (Figure 1). Presently, the majority of resettling populations receive predeparture albendazole making stool testing or treatment for soil-transmitted helminths (STH) unnecessary for most refugees. In addition, the majority of SSA populations have been presumptively treated for schistosomiasis with praziquantel; therefore, domestic testing and treatment for schistosomiasis are also not necessary for most refugees from SSA. Refugees arriving from the Middle East, Asia, and SSA countries that are not endemic for *L. loa* are at high risk for strongyloidiasis infection. If they have not been presumptively treated overseas with ivermectin, they should receive presumptive treatment with ivermectin after arrival or undergo testing followed by treatment, if positive. A table of
countries that are currently implementing these pre-departure presumptive treatments can be found here. It is anticipated that the implementation of predeparture presumptive treatment for strongyloidiasis may be expanded to other US-bound refugee populations in the future so clinicians should continue to check the CDC website for updated information.

Refugees from *L. loa* endemic SSA countries should not receive presumptive ivermectin due to the possible risk of encephalopathy associated with a high load of dying microfilaria. After arrival in the United States, they should undergo testing for strongyloidiasis. Those found to be infected may be treated with a longer course of high-dose albendazole (400 mg orally twice a day for 7 days). Alternatively, they may be screened for *L. loa* with a daytime blood smear and if not infected with *L. loa*, they can receive presumptive treatment with ivermectin.

The following sections recommend approaches for evaluating refugees during the post-arrival domestic medical visit based on whether the refugee had documented or presumed predeparture treatment. For the purposes of post-arrival management of parasites, refugees may be divided into three groups: no predeparture presumptive treatment, incomplete presumptive treatment, and complete presumptive treatment.

**No presumptive treatment**

Refugees in this category did not receive any presumptive treatment for parasites prior to departure for the United States. This group includes persons from populations not included in the table of presumptive treatment programs and those excluded due to contraindications to presumptive treatment with albendazole, praziquantel, and ivermectin. An algorithm has been developed to assist clinicians in managing patients who have received no predeparture therapy either because they were from a population not included in current programming, or if they had a contraindication at the time of departure (Figure 1).

- Albendazole contraindications:
  - Children < 1 year of age, pregnant women, refugees with known neurocysticercosis, evidence of cysticercosis (e.g., subcutaneous nodules), or with a history of unexplained seizures.

- Praziquantel contraindications:
  - Children < 4 years of age or measuring < 94 cm, refugees with known neurocysticercosis, evidence of cysticercosis (e.g., subcutaneous nodules), or with a history of unexplained seizures.

- Ivermectin contraindications:
  - Children < 15 kg or measuring < 90 cm, pregnant women in any trimester or breastfeeding women within the first week after birth.

- Refugee is departing from or has lived in a *Loa loa* endemic are:

**Incomplete presumptive treatment**

Refugees in this category did not receive all of the recommended overseas presumptive treatment for parasites prior to departure. An algorithm has been developed to assist clinicians on post-arrival management for those who received incomplete therapy (Figure 2).

- Most refugee populations are receiving single dose albendazole and it is reasonable to assume they have received albendazole if they are from populations included in the presumptive treatment programs and do not have a contraindication to albendazole.

- Most SSA refugees, are receiving predeparture praziquantel treatment for schistosomiasis if they are from populations included in the presumptive treatment programs and do not have a contraindication to praziquantel.
Complete presumptive treatment

Refugees in this category received all recommended treatments for overseas presumptive treatment for parasites prior to departure (Figure 3). A table of countries that are currently implementing these pre-departure presumptive treatments can be found here.

Finding information sources on presumptive treatment received

There have been substantial challenges in providing the records of presumptive parasite treatment for individual refugees to US clinicians at the time of their new arrival medical examination. Therefore, information and individual refugee presumptive treatment records are made available in multiple formats.

- **IOM Bag**: Records of presumptive predeparture treatment received by the refugee are usually available in the IOM bag, also known as the “blue and white bag,” carried by the refugee. The refugee should be directed to bring the IOM bag to the clinic at the time of appointment. The provider may also check with the voluntary resettlement agency coordinating the refugee’s care as they may have a copy of these records.

- **Electronic Disease Notification System (EDN)**: Records will be made available to Refugee Health Coordinators and some clinics through EDN. Clinicians may request this information from their respective state refugee health program.

- **CDC Website**: In addition, refugee populations receiving presumptive treatment will be listed on CDC’s website. A table of countries that are currently implementing these pre-departure presumptive treatments can be found here.

Summary of management of parasitic infections by population in asymptomatic refugees

**Management of asymptomatic refugees who received no predeparture treatment**

- A refugee who received no overseas predeparture antiparasitic treatment should receive either post-arrival presumptive treatment or post-arrival screening.

- If presumptive treatment is selected, follow the recommendations in Table 1. If screening is selected, follow the algorithm in Figure 1.

**Management of asymptomatic refugees who received incomplete presumptive treatment for parasitic infection**

- A refugee who received incomplete presumptive treatment overseas should receive either post-arrival presumptive treatment or post-arrival screening (Figure 2).

- If presumptive treatment is selected, follow the recommendations in Table 1.

Most refugees resettling in the United States who fall into this category have received albendazole and do not require routine stool O&P screening or presumptive treatment with albendazole. Although most refugees currently receive albendazole therapy, many are not receiving treatment for strongyloidiasis or schistosomiasis even though such treatment was indicated. Depending on which treatment was not received, the clinician will need to select the appropriate presumptive treatment or screen and treat strategy. Presumptive treatment for strongyloidiasis for refugees from non-Loa loa endemic countries is two doses of ivermectin given on two consecutive days (Tables 1). For those from Loa loa endemic areas, a screen and treat approach is usually more appropriate, although presumptive high-dose, long-course albendazole with or without screening is an acceptable alternative for presumptive treatment of Loa loa (Table 1). For SSA
refugees who have not received predeparture therapy for schistosomiasis, post-arrival presumptive treatment with praziquantel (Tables 1 or screening and treatment is indicated. Serologic testing is the most sensitive test for screening. Details on diagnostic tests available for Strongyloides and schistosomiasis in symptomatic patients are discussed below.

Management of asymptomatic refugees who received complete presumptive treatment for parasitic infection

- There is no need to screen asymptomatic refugees for parasitic infection if they received the complete treatment package (Figure 3).

However, it is common for arriving refugees to have a screening eosinophil count as part of their routine complete blood count (CBC) with differential. If elevated this may indicate infection and follow-up is recommended in Figure 3.

Screening and diagnostic tests for strongyloidiasis

Screening for strongyloidiasis involves serologic testing or stool culture. Stool ova and parasite examination may be used, but testing of three samples results in less than 60% sensitivity and up to 7 samples may be necessary to increase sensitivity to more than 90%. Serologic testing is the most widely available testing modality and positive results are sufficient to confirm the diagnosis. However, a combination of more than one testing technique may increase sensitivity and specificity (e.g., serology and stool ova and parasite testing). For SSA refugees who have lived in areas endemic for L. loa, screening for L. loa using a quantitative daytime blood smear or filariasis/Loa loa serology is necessary in order to determine the safety of ivermectin therapy. Refugees who are negative may be treated with ivermectin; those who are positive may be treated with high dose albendazole. Testing for Loa loa is not necessary if treating persons with strongyloidiasis with high-dose albendazole. Further information on loiasis is available on the CDC Division of Parasitic Diseases Website.

Screening and diagnostic tests for schistosomiasis

Serologic testing is the most sensitive test for screening for schistosomiasis. Stool ova and parasite testing may detect infection, although, similar to testing for strongyloidiasis, sensitivity can be quite low. Diagnosis of schistosomiasis can be made using stool, urine studies, or serologies. Refugees at risk for S. hematobium should have urine checked for ova. Schistosoma hematobium is endemic to much of Africa, parts of Arabia, the Middle East, and Khuzestan Province in Iran, Madagascar, and Mauritius. Those who are from areas endemic for the other schistosome species should have stool checked for ova to detect other species such as S. mansoni and S. japonicum. Standard stool studies are not as sensitive for schistosomiasis as for soil-transmitted helminths. When performing stool testing for schistosomiasis it is important to collect three specimens on three separate days. Although the Kato Katz method (staining a stool sample and examining under a microscope) is preferred, formalin preserved stool with concentration may also detect schistosome ova. Urine should also be collected three times on three separate days. Hematuria can be used as an indicator of infection in persons from endemic areas in SSA. Serologic testing is useful for diagnosis in populations that have never received praziquantel. Combining serology and stool testing may increase sensitivity and specificity in both screening and in diagnosis of disease. In addition, other findings on routine screening tests may suggest infection such as eosinophilia (e.g., strongyloidiasis, schistosomiasis) or hematuria (e.g., schistosomiasis), although these are non-specific findings.

Further information on individual parasites may be obtained from www.cdc.gov/parasites and assistance with diagnosis or management of parasitic diseases may be obtained through the CDC’s Parasitic Diseases Branch Public Inquiries Line at parasites@cdc.gov or 404-718-4745.

Persistent eosinophilia in refugee populations

Figure 3 describes management of baseline eosinophilia in an asymptomatic refugee who is tested upon resettlement in the United States. Ideally, the eosinophil count would be checked in refugees only 3-6 months after receipt of the complete presumptive treatment. In practice, most refugees receive a baseline eosinophil count as part of a CBC with differential done as part of the new arrival medical screening that occurs shortly after presumptive predeparture treatment and resettlement in the United States. If the
eosinophil count is normal, repeat testing for eosinophilia in an asymptomatic person is not indicated. If the absolute eosinophil count is \( \geq 400 \text{ cells/mL} \), clinical decision making should be based on the history of presumptive treatment.

- Refugees who received the complete presumptive treatment package should have their eosinophil count repeated in 3-6 months, as it can take this long for eosinophilia to resolve after appropriate treatment. No other testing is indicated in an asymptomatic refugee.

- If the refugee has not received the complete presumptive treatment package it is reasonable to provide the missing components of the complete treatment package (Table 1) and recheck eosinophil counts in 3-6 months after receipt of treatment prior to embarking on a diagnostic work-up. The most common etiologies of eosinophilia in asymptomatic refugee populations are soil-transmitted helminths, *Strongyloides*, and *Schistosoma* infections.

- If the refugee has not received the complete presumptive treatment package and the clinician opts for screening for parasitic infections in lieu of presumptive treatment, the work-up suggested in Figure 1 may be followed. The most common etiologies of eosinophilia in asymptomatic refugee populations are soil-transmitted helminths, *Strongyloides*, and *Schistosoma* infections.

If the eosinophilia persists 6 months after treatment, an evaluation of eosinophilia that includes other parasites (other than soil-transmitted helminths, *Strongyloides*, and *Schistosoma* infections) as well as non-parasitic causes should be considered.  

Other parasitic infections commonly encountered in refugees

There are many parasitic infections encountered in refugees which may be detected as a result of solicited symptoms such as abdominal pain (e.g., *Hymenolepis nana*) or seizures (cystercercosis), physical examination (e.g., filariasis, onchocerciasis), laboratory abnormalities such as persistent eosinophilia (e.g., liver or lung flukes) or as incidental findings on stool examination (e.g., protozoal infections). Further information on these parasitic infections and assistance with diagnosis and treatment may be provided by the [Centers for Disease Control and Prevention’s Division of Parasitic Diseases](http://www.cdc.gov/parasites/).

**Table 1. Recommended medication regimen for presumptive treatment of parasitic infections**

<table>
<thead>
<tr>
<th>Refugee Population</th>
<th>Regimens by Pathogen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Soil-transmitted helminths: Albendazole</td>
</tr>
<tr>
<td>Adults</td>
<td>Strongyloidiasis: Ivermectin or high-dose albendazole</td>
</tr>
<tr>
<td></td>
<td><em>Schistosomiasis</em>: Praziquantel¹</td>
</tr>
<tr>
<td>Asia, Middle East, and North Africa,</td>
<td></td>
</tr>
<tr>
<td>Latin America and Caribbean</td>
<td>400 mg orally for 1 day</td>
</tr>
<tr>
<td></td>
<td>Ivermectin, 200 ( \mu \text{g/kg/day} ) orally once a day for 2 days</td>
</tr>
<tr>
<td></td>
<td>Not recommended</td>
</tr>
<tr>
<td>Sub-Saharan Africa, non-<em>Loa loa</em>-endemic area</td>
<td>400 mg orally for 1 day</td>
</tr>
<tr>
<td></td>
<td>Ivermectin, 200 ( \mu \text{g/kg/day} ) once a day for 2 days</td>
</tr>
<tr>
<td></td>
<td>Praziquantel¹, 40 ( \mu \text{g/kg} ) (may be divided and given in two doses for better tolerance).</td>
</tr>
<tr>
<td>Sub-Saharan Africa, <em>Loa loa</em>-endemic area</td>
<td>400 mg orally for 1 day</td>
</tr>
<tr>
<td></td>
<td>Only use ivermectin (200 ( \mu \text{g/kg/day} ) once a day for 2 days) if <em>Loa loa</em> infection has been ruled out. May use high dose albendazole (400 mg twice a day for 7 days) if <em>Loa loa</em> infection cannot be ruled out. For more</td>
</tr>
<tr>
<td></td>
<td>Praziquantel¹, 40 ( \mu \text{g/kg} ) (may be divided and given in two doses for better tolerance).</td>
</tr>
</tbody>
</table>
Pregnant women

Asia, the Middle East/North Africa, Latin America and Caribbean
Not recommended
Not recommended
Not recommended

Sub-Saharan Africa
Not recommended
Not recommended
Praziquantel, 40 mg/kg (may be divided and given in two doses for better tolerance).

Children

Asia, the Middle East/North Africa, Latin America and Caribbean
12-23 months of age: 200 mg orally for 1 day. Presumptive therapy is not recommended for any infant less than 12 months of age.
Ivermectin, 200 μg/kg/day orally once a day for 2 days Should not be used presumptively if ≤15 kg or from Loa loa-endemic country.
Not recommended

Sub-Saharan Africa
12-23 months of age: 200 mg orally for 1 day. Presumptive therapy is not recommended for any infant less than 12 months of age.
Ivermectin, 200 μg/kg/day orally once a day for 2 days Should not be used presumptively if ≤15 kg or from Loa loa-endemic country.
Children under < 4 years of age should not receive presumptive treatment with praziquantel. Only for children from sub-Saharan Africa

Although WHO states ivermectin and albendazole may be given concurrently, it is recommended that ivermectin be taken on an empty stomach and albendazole with fatty foods.

Praziquantel, if not co-administered, should be administered at least one day prior to either ivermectin or albendazole. Praziquantel should be taken with liquids during a meal.

All sub-Saharan African countries are considered endemic for schistosomiasis except Lesotho.

Table 2. Common parasites detected on stool examination

<table>
<thead>
<tr>
<th>Pathogenic</th>
<th>Controversial</th>
<th>Other</th>
<th>Nonpathogenic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nematodes</strong></td>
<td><strong>Trematodes</strong></td>
<td><strong>Cestodes</strong></td>
<td><strong>Protozoa</strong></td>
</tr>
<tr>
<td>Ascaris lumbricoides</td>
<td>Schistosoma (S. mansoni, S. haematobium, S. japonicum)</td>
<td>Taenia solium</td>
<td>Entamoeba histolytica*</td>
</tr>
<tr>
<td>Necator americanus &amp; Ancylostoma duodenale</td>
<td>Other flukes (Ophisthorchis spp.) Fasciola, Paragonimus westermani</td>
<td>Taenia saginatum</td>
<td>Giardia intestinalis (also known as G. lamblia or G. duodenalis)</td>
</tr>
<tr>
<td>Trichuris trichiura</td>
<td>Strongyloides stercoralis</td>
<td>Hymenolepis nana</td>
<td>Dientamoeba fragilis (diarrhea)</td>
</tr>
<tr>
<td>*The cyst of *E. histolytica, *E. dispar and <em>E. moshkovskii</em> are morphologically identical by stool microscopy (morphologically). When cysts are detected, stool antigen testing is recommended distinguish the potentially pathogenic <em>E. histolytica</em> from the more common, non-pathogenic species.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Table 3. Causes of eosinophilia

<table>
<thead>
<tr>
<th>Parasites that cause eosinophilia commonly found in stool examination</th>
<th>Other parasitic infections associated with eosinophilia</th>
<th>Parasites commonly found in the stool NOT typically associated with eosinophilia</th>
<th>Non-parasitic causes of eosinophilia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascaris lumbricoides</td>
<td>Angiostrongylus, Anakalis, Capillaria spp., Cysticercosis</td>
<td>Entamoeba spp. (histolytica, dispar, other Entamoeba spp.)</td>
<td>Asthma</td>
</tr>
<tr>
<td>Hookworm (Ancylostoma spp, Necator spp)</td>
<td>Echinococcus spp.</td>
<td>Giardia intestinalis (also known as G. lamblia or G. duodenalis)</td>
<td>Atopy</td>
</tr>
<tr>
<td>Trichuris trichiura</td>
<td>Filariaasis (Wuchereria bancrofti, Brugia spp, Mansonella spp, Onchocerca volvulus, Dracunculus medinensis, Loa loa)</td>
<td></td>
<td>Drug allergy</td>
</tr>
<tr>
<td>Strongyloides stercoralis*</td>
<td></td>
<td>Schistosoma (most commonly S. mansoni*, S. japonicum*)</td>
<td>Eosinophilic leukemia</td>
</tr>
<tr>
<td>Tapeworm (Taenia solium and T. saginatum)</td>
<td></td>
<td>Schistosoma (most commonly S. mansoni*, S. haematobium*, S. japonicum*)</td>
<td>Hodgkin’s lymphoma</td>
</tr>
<tr>
<td>Schistosoma (most commonly S. mansoni*, S. japonicum*)</td>
<td></td>
<td></td>
<td>Hyper-eosinophilic syndrome</td>
</tr>
<tr>
<td>Other flukes (Paragonimus spp.<em>, Ophisthorchis spp.</em>, Fasciola spp.*)</td>
<td></td>
<td></td>
<td>Pemphigoid</td>
</tr>
<tr>
<td>Other parasitic infections associated with eosinophilia</td>
<td></td>
<td></td>
<td>Pemphigus</td>
</tr>
<tr>
<td>Non-parasitic causes of eosinophilia</td>
<td></td>
<td></td>
<td>Polyarteritis nodosa</td>
</tr>
</tbody>
</table>

*Particularly common causes of eosinophilia which may be found in stool but special testing and/or multiple samples are frequently needed.

### References

Figure 2. Management of parasitic infections for refugee population currently receiving parasitic pre-departure presumptive albendazole but incomplete pre-departure therapy as of March 1, 2013

- **Sub-Saharan African refugees**
  - Presumptive praziquantel?
    - Yes
      - Presumptive ivermectin?
        - Yes
          - CBC with differential
        - No
          - CBC with differential PLUS Presumptive therapy with ivermectin OR screen and treat for Strongyloides
    - No
      - Originating or from *Loa loa*-endemic area?
        - Yes
          - CBC with differential PLUS Screen for *Strongyloides* and *Loa* and treat *Strongyloides* if not contraindicated
        - No
          - Eosinophilia?
            - Yes
              - Recheck total eosinophil count in 3-6 months
            - No
              - Further evaluation only if symptomatic
                - Eosinophilia?
                  - Yes
                    - Further evaluation of etiology of eosinophilia
                  - No
                    - Further evaluation only if symptomatic
Figure 3. Management of parasitic infection for asymptomatic refugees who received complete pre-departure therapy as of March 1, 2013

All refugees

CBC with differential

Eosinophilia?

Yes

Re-check total eosinophil count in 3-6 months

Eosinophilia?

Yes

Further evaluation of etiology of eosinophilia

No

Further evaluation only if symptomatic

Yes

Further evaluation only if symptomatic

Eosinophilia?

No

Further evaluation only if symptomatic

---

1 Complete blood count and differential (not recommended as screening test for parasitic infection but routinely obtained on screening for newly arrived immigrants and refugees)

2 Eosinophilia = an eosinophil count of >400 μL
Treatment Schedules for Presumptive Parasitic Infections for U.S.-Bound Refugees, administered by IOM\textsuperscript{a}—May 2013
Prepared by Immigrant, Refugee and Migrant Health Branch, Division of Global Migration and Quarantine, CDC

This table describes presumptive anti-parasitic treatment currently provided to the largest groups of U.S.-bound refugees. The first three columns list the region, departure country, and ethnicity/national origin of the refugees. The fourth column lists recommended presumptive treatment for parasites (including malaria).

<table>
<thead>
<tr>
<th>Region</th>
<th>Country of Processing</th>
<th>Principal Refugee Groups (location)</th>
<th>Presumptive Parasite Treatment for Eligible Refugees\textsuperscript{bc}</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>Ethiopia</td>
<td>Eritreans (Shimelba); Somalis (Kebribe); Multiple (Addis Ababa)</td>
<td>Albendazole; Praziquantel; Artemether-lumefantrine</td>
<td>Artemether-lumefantrine since Oct 2007</td>
</tr>
<tr>
<td></td>
<td>Kenya</td>
<td>Somalis (Dadaab); Somalis, Sudanese, Congolese (Kakuma); Multiple (Nairobi)</td>
<td>Albendazole; Praziquantel; Artemether-lumefantrine</td>
<td>Artemether-lumefantrine since fall 2007</td>
</tr>
<tr>
<td></td>
<td>Tanzania</td>
<td>Congolese, Burundians (Kigoma)</td>
<td>Albendazole; Praziquantel; Artemether-lumefantrine</td>
<td>Artemether-lumefantrine since July 2007</td>
</tr>
<tr>
<td></td>
<td>Rwanda, South Africa, Uganda</td>
<td>Somalis, Congolese</td>
<td>Albendazole; Praziquantel; Artemether-lumefantrine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Malaysia</td>
<td>Burmese (Kuala Lumpur)</td>
<td>Albendazole; Ivermectin</td>
<td>-Albendazole for children 1-2 yo since Nov 2011</td>
</tr>
<tr>
<td></td>
<td>Nepal</td>
<td>Bhutanese (Beldangi, Sanischare, Khudunabari); other (urban)</td>
<td>Albendazole; Ivermectin</td>
<td>-Ivermectin, since Feb 2013</td>
</tr>
<tr>
<td></td>
<td>Thailand</td>
<td>Burmese (Thailand-Burma border); other (urban)</td>
<td>Albendazole; Ivermectin</td>
<td>-Albendazole for children 1-2 yo since Feb 2012</td>
</tr>
<tr>
<td></td>
<td>Iraq</td>
<td>Iraqis (Baghdad, Al Walid camp)</td>
<td>Albendazole</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jordan</td>
<td>Iraqis (Amman)</td>
<td>Albendazole</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lebanon, Syria, Turkey, Egypt</td>
<td>Multiple</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Mideast</td>
<td>Russia, Ukraine, Moldova</td>
<td>Russians, Afghanis, Ukrainians, Moldovans</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td>Cuba, other</td>
<td>Cubans, Colombians</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{a} Information provided by the International Organization for Migration (IOM) during required overseas refugee medical exam
\textsuperscript{b} Presumptive parasite treatments: Albendazole (for soil-transmitted helminths), 400 mg for refugees ≥ 2 yo; Albendazole, 200 mg for those 1-2 yo; Ivermectin (for strongyloides), 200 µg/kg x 2 d; and Praziquantel (for schistosomiasis), 40 mg/kg divided in 2 doses. See http://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/intestinal-parasites-overseas.html
\textsuperscript{c} Artemether-lumefantrine (AL, for malaria) 6-dose treatment. See http://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/malaria-guidelines-overseas.html
\textsuperscript{c} Over 75\% compliance rates with administration of presumptive parasite treatment have been documented for the countries listed on this table. If a country does not appear on this table, then compliance rates in that country are uncertain, so clinicians should use their judgment on a screening vs. presumptive treatment approach.